HC Wainwright & Co. analyst Douglas Tsao maintains Dare Bioscience (NASDAQ:DARE) with a Buy and raises the price target from $5 to $6.
Keybanc Maintains Overweight on Hub Group, Raises Price Target to $105
Keybanc analyst Todd Fowler maintains Hub Group (NASDAQ:HUBG) with a Overweight and raises the price target from $95 to $105.